Triumeq ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 3 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05193994 (ClinicalTrials.gov) | February 24, 2022 | 6/12/2021 | Triumeq in Amyotrophic Lateral Sclerosis | Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Dolutegravir, Abacavir and Lamivudine;Drug: Placebo | Macquarie University, Australia | King's College London;Stichting TRICALS Foundation | Recruiting | 18 Years | N/A | All | 390 | Phase 3 | Australia |
| 2 | EUCTR2020-005069-15-NL (EUCTR) | 23/06/2021 | 14/04/2021 | LIGHTHOUSE 2 | RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - Lighthouse 2 | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Triumeq Product Name: Triumeq INN or Proposed INN: Dolutegravir INN or Proposed INN: Abacavir INN or Proposed INN: Lamivudine | Stichting TRICALS Foundation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 390 | Phase 3 | Australia;Netherlands;United Kingdom | ||
| 3 | NCT02868580 (ClinicalTrials.gov) | October 2016 | 16/6/2016 | Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). | Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project. | Amyotrophic Lateral Sclerosis | Drug: Triumeq | Neuroscience Trials Australia | Macquarie University, Australia;Westmead Hosptial;Calvary Health Care Bethlehem;The University of Sydney - Brain and Mind Centre | Completed | 18 Years | 75 Years | All | 43 | Phase 2 | Australia |